Neuroprotective potential of mGluR5 antagonist MTEP: Effects on kainate-induced excitotoxicity in the rat hippocampus

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 1051-1061

  Domin, Helena ^a   Ziȩba, Barbara ^a   Gołembiowska, Krystyna ^a   Kowalska, Magdalena ^a   Dziubina, Anna ^a   Śmiałowska, Maria ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

3 (2 methyl 1,3 thiazol 4 yl)ethynyl pyridine (MTEP); Excitotoxicity; Hippocampus; Kainic acid; mGlu5 antagonist; Neuroprotection

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; GLUTAMIC ACID; KAINIC ACID; METABOTROPIC RECEPTOR 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DRUG MECHANISM; EXCITOTOXICITY; HIPPOCAMPAL CA1 REGION; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MICRODIALYSIS; MICROINJECTION; NEUROPROTECTION; NONHUMAN; RAT;

EID: 79551493747     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70367-4     Document Type: Article

References (70)

1. Allen JW, Knoblach SM, Faden AI: Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death in vitro. Cell Death Differ, 2000, 7, 470-476.
2. 3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur J Pharmacol, 2003, 473, 35-40.
3. 3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl] pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther, 2002, 303, 1044-1051.
4. Arundine M, Tymianski M: Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium, 2003, 34, 325-337.
5. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ: Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci, 2000, 20, 7871-7879.
6. Bao WL, Williams AJ, Faden AI, Tortella FC: Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia. Brain Res, 2001, 922, 173-179.
7. Battaglia G, Bruno V, Pisani A, Centonze D, Catania MV, Calabresi P, Nicoletti F: Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing gabaergic transmission. Mol Cell Neurosci, 2001, 17, 1071-1083.
8. Battaglia G, Fornai F, Busceti CL, Aloisi G, Cerrito F, De Blasi A, Melchiorri D, Nicoletti F: Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J Neurosci, 2002, 22, 2135-2141.
9. Bruno V, Copani A, Knöpfel T, Kuhn R, Casabona G, Dell'Albani P, Condorelli DF, Nicoletti F: Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells. Neuropharmacology, 1995, 34, 1089-1098.
10. Bruno V, Ksiazek I, Battaglia G, Lukic S, Leonhardt T, Sauer D, Gasparini F et al.: Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology, 2000, 39, 2223-2230. (Pubitemid 30642765)
11. Busse CS, Brodkin J, Tattersall D, Anderson JJ, Warren N, Tehrani L, Bristow LJ et al.: The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology, 2004, 29, 1971-1979.
12. Byrnes KR, Loane DJ, Faden AI: Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders. Neurotherapeutics, 2009, 6, 94-107. Review.
13. Byrnes KR, Stoica B, Riccio A, Pajoohesh-Ganji A, Loane DJ, Faden AI: Activation of metabotropic glutamate receptor 5 improves recovery after spinal cord injury in rodents. Ann Neurol, 2009, 66, 63-74.
14. Chittajallu R, Vignes MDev KK, Barnes JM, Collingridge GL, Henley JM: Regulation of glutamate release by presynaptic kainate receptors in the hippocampus. Nature, 1996, 379, 78-81.
15. Choi DW: Excitotoxic cell death. J Neurobiol, 1992, 23, 1267-1276.
16. Conn PJ, Pin JP: Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol, 1997, 37, 205-237.
17. 3H]-methoxy- PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett, 2003, 13, 351-354.
18. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L et al.: 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem, 2003, 46, 204-206. (Pubitemid 36078139)
19. Coyle JT: Neurotoxic action of kainic acid. J Neurochem, 1983, 41, 1-11.
20. Danysz W, Parsons CG: Glycine and N-methyl-D-asparate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev, 1998, 50, 597-664.
21. Domin H, Kajta M, Śmiałowska M: Neuroprotective effects of MTEP, a selective mGluR5 antagonists and neuropeptide Y on the kainate-induced toxicity in primary neuronal cultures. Pharmacol Rep, 2006, 58, 846-858.
22. Fazal A, Parker F, Palmer AM, Croucher MJ: Characterisation of the actions of group I metabotropic glutamate receptor subtype selective ligands on excitatory amino acid release and sodium-dependent re-uptake in rat cerebrocortical minislices. J Neurochem, 2003, 86, 1346-1358.
23. Ferkany JW, Coyle JT: Kainic acid selectively stimulates the release of endogenous excitatory acidic amino acids. J Pharmacol Exp Ther, 1983, 225, 399-406.
24. Ferkany JW, Zaczek R, Coyle JT: Kainic acid stimulates excitatory amino acid neurotransmitter release at presynaptic receptors. Nature, 1982, 298, 757-759.
25. Flor PJ, Battaglia G, Nicoletti F, Gasparini F, Bruno V: Neuroprotective activity of metabotropic glutamate receptor ligands. Adv Exp Med Biol, 2002, 513, 197-223.
26. Gołembiowska K, Dziubina A: Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum. Brain Res, 2004, 998, 208-217.
27. 2A receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology, 2004, 47, 414-426.
28. Gołembiowska K, Konieczny J, Wolfarth S, Ossowska K: Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats. Neuropharmacology, 2003, 45, 484-492.
29. Gundersen HJ, Jensen EB: The efficiency of systematic sampling in stereology and its prediction. J Microsc, 1987, 147, 229-263.
30. Ikonomidou C, Turski L: Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurology, 2002, 1, 383-386.
31. Jesse CR, Savegnago L, Rocha JB, Nogueira CW: Neuroprotective effect caused by MPEP, an antagonist of metabotropic glutamate receptor mGluR5, on seizures induced by pilocarpine in 21-day-old rats. Brain Res, 2008, 1198, 197-203.
32. Knecht R, Chang JY: Liquid chromatographic determination of amino acids after gas-phase hydrolysis and derivatization with (dimethylamino) azobenzenesulfonyl chloride. Anal Chem, 1986, 58, 2375-2379.
33. 3H]R214127. Neuropharmacology, 2004, 46, 609-619.
34. Lea IV PM, Faden AI: Modulation of metabotropic glutamate receptors as potential treatment for acute and chronic neurodegenerative disorders. Drug News Perspect, 2003, 16, 513-522.
35. Lea IV PM, Movsesyan VA, Faden AI: Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Br J Pharmacol, 2005, 145, 527-534.
36. Makarewicz D, Duszczyk M, Gadamski R, Danysz W, Łazarewicz JW: Neuroprotective potential of group I metabotropic glutamate receptor antagonists in two ischemic models. Neurochem Int, 2006, 48, 485-490.
37. Malva JO, Carvalho AP, Carvalho CM: Kainate receptors in hippocampal CA3 subregion: evidence for a role in regulating neurotransmitter release. Neurochem Int, 1998, 32, 1-6.
38. Mattson MP: Calcium and neurodegeneration. Aging Cell, 2007, 6, 337-350.
39. Moroni F, Cozzi A, Lombardi G, Sourtcheva S, Leonardi P, Carfì M, Pellicciari R: Presynaptic mGlu1 type receptors potentiate transmitter output in the rat cortex. Eur J Pharmacol, 1998, 347, 189-195.
40. Movsesyan VA, O'Leary DM, Fan L, Bao W, Mullins PG, Knoblach SM, Faden AI: mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6- (2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors. J Pharmacol Exp Ther, 2001, 296, 41-47.
41. Muir KW, Lees KR: Clinical experience with excitatory amino acid antagonist drugs. Stroke, 1995, 26, 503-513.
42. Muly EC, Maddox M, Smith Y: Distribution of mGluR1α and mGluR5 immunolabeling in primate prefrontal cortex. J Comp Neurol, 2003, 467, 521-535.
43. Nadler JV, Perry BW, Cotman CW: Intraventricular kainic acid preferentially destroys hippocampal pyramidal cells. Nature, 1978, 271, 676-677.
44. Nicoletti F, Bruno V, Catania MV, Battaglia G, Copani A, Barbagallo G, Ceña V et al.: Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection. Neuropharmacology, 1999, 38, 1477-1484.
45. Nicoletti F, Bruno V, Copani A, Casabona G, Knöpfel T: Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci, 1996, 19, 267-271.
46. O'Leary DM, Movsesyan V, Vicini S, Faden AI: Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br J Pharmacol, 2000, 131, 1429-1437.
47. Olney JW: Neurotoxicity of excitatory amino acids. In: Kainic Acid as a Tool in Neurobiology. Ed. McGeer EG, Olney JW, McGeer PL, Raven Press, New York, 1978, 95-121.
48. Olney JW, Ishimaru MJ: Excitotoxic cell death. In: Cell Death and Diseases of the Nervous System. Ed. Koliatsos VE, Ratan RR, Humana Press, Totowa NJ, 1999, 197-220.
49. Ossowska K, Konieczny J, Wolfarth S, Pilc A: MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology, 2005, 49, 447-455.
50. Ossowska K, Śmiałowska M, Kuter K, Wieroñska J, Ziȩba B, Wardas J, Nowak P et al.: Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease. Neuroscience, 2006, 141, 2155-2165.
51. Ossowska K, Wardas J, Śmiałowska M, Kuter K, Lenda T, Wieroñska JM, Ziȩba B et al.: A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease? Eur J Neurosci, 2005, 22, 1294-1304.
52. Pałucha A, Brañski P, Szewczyk B, Wieroñska JM, Kłak K, Pilc A: Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav, 2005, 81, 901-906.
53. Paxinos G, Watson C: The rat brain in stereotaxic coordinates, 2nd ed., Academic Press, San Diego, CA, 1986.
54. Pilc A: The metabotropic glutamate receptors (mGluR) in neuroprotection. In: Neuroprotection (in Polish). XX Winter School of the Institute of Pharmacology PAS, Mogilany. Ed. Śmiałowska M., IF PAS, Kraków 2003, 29-39.
55. Pintor A, Pèzzola A, Reggio R, Quarta D, Popoli P: The mGlu5 receptor agonist CHPG stimulates striatal glutamate release: possible involvement of A2A receptors. Neuroreport, 2000, 11, 3611-3614.
56. Pisani A, Gubellini P, Bonsi P, Conquet F, Picconi B, Centonze D, Bernardi G, Calabresi P: Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience, 2001, 106, 579-587.
57. Popoli P, Pintor A, Tebano MT, Frank C, Pepponi R, Nazzicone V, Grieco R et al.: Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid-induced striatal toxicity: involvement of pre- and post-synaptic mechanisms and lack of direct NMDA blocking activity. J Neurochem, 2004, 89, 1479-1489.
58. Rao AM, Hatcher JF, Dempsey RJ: Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil. Neurosci Lett, 2000, 293, 1-4.
59. Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN, Olney JW: Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol, 1995, 355, 455-469.
60. Shigemoto R, Nakanishi S, Mizuno N: Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat. J Comp Neurol, 1992, 322, 121-135.
61. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, Mizuno N: Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett, 1993, 163, 53-57. (Pubitemid 23349393)
62. Skolnick P: Antidepressants for the new millennium. Eur J Pharmacol, 1999, 375, 31-40.
63. Stone TW, Addae JI: The pharmacological manipulation of glutamate receptors and neuroprotection. Eur J Pharmacol, 2002, 447, 285-296.
64. Szydlowska K, Kaminska B, Baude A, Parsons CG, Danysz W: Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo. Eur J Pharmacol, 2007, 554, 18-29.
65. Śmiałowska M, Domin H, Ziȩba B, Koźniewska E, Michalik R, Piotrowski P, Kajta M: Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo. Neuropeptides, 2009, 43, 235-249.
66. Śmiałowska M, Wieroñska JM, Szewczyk B: Neuroprotective effect of NPY on kainate neurotoxicity in the hippocampus. Pol J Pharmacol, 2003, 55, 979-986.
67. 5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidence. Neuropharmacology, 2001, 41, 523-527.
68. 5 subtype positively modulate neuronal glutamate release in the rat forebrain in vitro. Neuropharmacology, 2000, 39, 1554-1566.
69. Ugolini A, Corsi M, Bordi F: Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons. Neuropharmacology, 1999, 38, 1569-1576.
70. Vernon AC, Palmer S, Datla KP, Zbarsky V, Croucher MJ, Dexter DT: Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur J Neurosci, 2005, 22, 1799-1806.